Response to adjuvant bevacizumab among patients with resected melanoma may vary by age
Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not, according to results published in ...
Oct 23, 2020
0
0